A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Author: Clot Connect

  • Prescription Assistance: When Patients Can’t Afford a Medication

    Beth Waldron, Program Director of the Clot Connect project, writes…. While the cost of some outpatient anticoagulation therapies can be substantial, failure to take an anticoagulant medication as prescribed can have serious, even deadly, consequences.   Links to resources which may help patients when they are prescribed an anticoagulant that they cannot afford is available in this article.…

  • Thrombosis and Hemostasis Conference 2012

    A major North American thrombosis & hemostasis  conference will take place May 3-5, 2012, in Chicago at the Hyatt Regency.  This meeting is mostly geered towards health care professionals of various specialties  interested in and taking care of patients with thrombotic and bleeding disorders.  It will provide state-of -the-art clinical management updates and relevant research developments, as well…

  • Savaysa (Edoxaban): New Oral Anticoagulant

    Edoxaban (Savaysa®), the 4th of the big new oral anticoagulants in development (the other big 3 being Dabigatran = Pradaxa, Rivaroxaban = Xarelto, and Apixaban = Eliquis), is now commercially available in Japan (July 19th, 2011 press release here), available as once daily dosing for VTE prevention after orthopedic surgeries (hip and knee replacement and…

  • LMWH Injections – Making it Easier: Insuflon Ports

    Once or twice daily injections of s.c. anticoagulants for prolonged periods of time can be bothersome and unacceptable for the patient. Use of a once weekly exchanged s.c. port, called Insuflon, can make longer-term s.c. anticoagulant therapy easier and more tolerable.

  • Postpartum – Safe Contraceptive Methods

    The CDC today published recommendations on use of contraceptive methods for non-breast feeding women in the post-partum period (full text is here).  The key recommendations are as follows:

  • Xarelto (Rivaroxaban) – FDA Approved

    Today the FDA approved the oral anticoagulant Xarelto (rivaroxaban) for DVT prevention in patients undergoing knee or hip replacement surgery.  This is good news

  • Pulmonary Hypertension after PE – CTEPH

    Pulmonary hypertension affects up to 4 % of PE patient and typically occurs within the first 2 years after a PE.  It is defined as a mean pulmonary artery pressure of ≥ 25 mm Hg by right heart catheterization, with normal pulmonary capillary wedge pressure, and elevated pulmonary vascular resistance.  Pulmonary hypertension occurring after an…

  • Apixaban (Eliquis): Good News

    Eliquis (Apixaban) is one of the 4 promising new oral anticoagulants that (a) do not require routine monitoring of its anticoagulant effect and (b) work independently of the vitamin K pathway.